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Introduction: Cancer pain creates a poor quality of life and decreases survival. The basic neurobiology of cancer
pain is poorly understood. Adenosine triphosphate (ATP) and the ATP ionotropic receptor subunits, P2X2 and P2X3,
mediate cancer pain in animal models; however, it is unknown whether this mechanism operates in human, and if so,
what the relative contribution of P2X2- and P2X3-containing trimeric channels to cancer pain is. Here, we studied head
and neck squamous cell carcinoma (HNSCC), which causes the highest level of function-induced pain relative to other
types of cancer.
Results: We show that the human HNSCC tissues contain significantly increased levels of ATP compared to the
matched normal tissues. The high levels of ATP are secreted by the cancer and positively correlate with self-reported
function-induced pain in patients. The human HNSCC microenvironment is densely innervated by nerve fibers
expressing both P2X2 and P2X3 subunits. In animal models of HNSCC we showed that ATP in the cancer
microenvironment likely heightens pain perception through the P2X2/3 trimeric receptors. Nerve growth factor (NGF),
another cancer-derived pain mediator found in both human and mouse HNSCC, induces P2X2 and P2X3 hypersensitivity
and increases subunit expression in murine trigeminal ganglion (TG) neurons.
Conclusions: These data identify a key peripheral mechanism in cancer pain and highlight the clinical potential of
specifically targeting nociceptors expressing both P2X2 and P2X3 subunits (e.g., P2X2/3 heterotrimers) to alleviate
cancer pain.
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Despite recent advances in cancer treatment, pain control
persists as an important clinical challenge, especially since
cancer patients are living longer [1]. Among all cancers,
head and neck (H&N) cancer is one of the most painful
[2,3]. H&N cancer pain typically locates at the primary site
and significantly impairs speech, swallowing, and mastica-
tory function [2,4]. The peripheral mechanism underlying
H&N cancer pain is not clearly understood.
In the peripheral nervous system, extracellular adeno-
sine triphosphate (ATP) contributes to nociception by
activation or sensitization of P2X receptors [5,6]. P2X2* Correspondence: bls322@nyu.edu
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unless otherwise stated.and P2X3 are mostly expressed in nociceptive sensory
neurons and participate in transduction of painful signals
[7]. P2X2 and P2X3 subunits can form homotrimeric
P2X2, P2X3, or heterotrimeric P2X2/3 receptors, each
with unique pharmacological properties. The different
receptor subtypes might mediate different pathological
pain conditions. Activation of P2X3 homotrimers by ATP
leads to a transient current with rapid desensitization,
whereas activation of P2X2 homotrimers by ATP leads
to a sustained current; activation of P2X2/3 heterotri-
mers by ATP leads to a current with intermediate
desensitization kinetics [8,9]. In rodents P2X3 subunits
are highly expressed on small-to-medium size sensory
neurons, while P2X2 subunits are expressed on medium-
to-large sensory neurons, and colocalization of P2X2 and
P2X3 subunits (putative P2X2/3 heterotrimers) are mainly
found on medium sized neurons [7]. It has been suggestedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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while P2X2/3 heterotrimers mediate chronic pain [10,11].
Recent animal studies highlight a role for ATP and its
purinergic receptors containing P2X3 subunits in bone
cancer pain [12-15]. The selective P2X3, P2X2/3 recep-
tor antagonist A-317491 transiently attenuates cancer-
induced bone pain in mice, but has no effect at the late
stage of bone cancer [13]. Bone cancer pain in rats is
reduced by the blockade of P2X3 and P2X2/3 receptors
with AF-353 [14]. However, these findings in animal
models do not necessarily translate into human physiology
[16] and there is no direct evidence to show whether ATP
correlates with pain in cancer patients. In addition, oral
cancer is distinct from bone cancer pain. Oral cancer
produces pain at the primary site whether it involves
the submucosa, muscle or jaws. Bone cancer pain is
almost always due to metastasis from another primary
site. The mechanism of ATP and purinergic signaling in
oral cancer pain is not as well characterized as it is in
the bone cancer pain model. Whereas P2X2 and P2X3
subunit immunoreactivities are readily detectable in
dorsal root ganglia (DRGs) and TG and in tongues of
rats and mice [17-21], human DRG reportedly express
P2X3 but not P2X2 mRNA [16], and human TG have
not been studied for P2X2 expression. Furthermore, the
cancer microenvironment contains many other media-
tors such as NGF [22], that could affect P2X2 and P2X3
expression, pharmacology and electrophysiological
response in sensory neurons [18,23,24]. Increased
expression of P2X3 subunits were reported in peripheral
tissues as well as DRGs in bone cancer pain models
[15,25]. Compared to well-studied P2X3 subunits, the role
of P2X2 subunits in cancer pain is less clear.
Here we used a translational approach investigating the
contribution of peripheral ATP and the differential roles
of P2X2 and P2X3 subunits in pain induced by HNSCC, a
cancer notoriously painful in patients [4]. We further
investigated whether NGF, a key tumor-derived medi-
ator of HNSCC pain and proliferation [22], modulated
P2X2 and P2X3 receptor expression, pharmacological
function and electrophysiological response. Our find-
ings have immediate implications on our understanding of
cancer pain in patients, and the development of potentially
beneficial pharmacological treatments targeted at the
ATP/P2X system.
Methods
The study was approved by the Institutional Review
Board of New York University College of Dentistry and
University of California San Francisco (UCSF). All patients
provided written informed consent in accordance with the
Declaration of Helsinki. Patients were enrolled with the
following inclusion criteria: 1) biopsy-proven HNSCC,
and 2) no history of prior surgical, chemotherapeutic, orradiation treatment for oral SCC. The validated UCSF
Oral Cancer Pain Questionnaire [26] was administered to
enrolled patients. The questionnaire consisted of eight
questions on spontaneous and functional pain, which were
rated on a visual analog scale (0 to 100 mm). None of
the patients were taking analgesics or were receiving
cancer treatment at the time of questionnaire comple-
tion. Demographic information was collected for each
patient including age, sex, ethnicity, HNSCC location
(tongue, floor of mouth, buccal mucosa, gingiva, palate),
tumor size (greatest dimension based on clinical exam-
ination), and evidence of metastasis.
Animals
Female athymic, immunocompromised (BALB/c nu/
nu) mice and BALB/c mice were purchased from
Charles River Laboratories. All experiments were per-
formed according to the policies of the International
Association for the Study of Pain and approved by the
New York University Institution Animal Care and Use
Committee.
HPLC analysis
HNSCC and anatomically matched, contralateral normal
oral epithelium from 13 oral cancer patients were surgi-
cally removed, immediately snap frozen in liquid nitrogen
and stored at −80°C. ATP was quantified with HPLC
coupled to UV detection. Each tissue sample was weighed
and ground in 10% Trichloroacetic acid buffer (MP Bio-
medical). Samples were incubated on ice for 1 hour, and
were periodically vortexed for 3 seconds. After incubation,
samples were centrifuged for 15 min at 10000 rpm in 4°C.
The supernatant was collected into pre-cooled centrifuge
tubes and neutralized with 0.2 M K2HPO4. The sample
was kept on ice for an additional 15 minutes to precipitate
the insoluble salts and centrifuged again for 10 minutes at
10000 rpm at 4°C. The resulting supernatant was decanted
into a collecting tube, drawn into a 1 ml syringe and
passed through a 0.22 μM filter (Fisher Scientific). The
samples were then transferred to vials and injected at a
volume of 10 μl into the HPLC system equipped with a
Waters 2795 Separations Module Microsampler (Waters
Corporation). The mobile phase was pumped at 1 ml/min
and consisted of 0.1 M KH2PO4, pH 5.0. Samples were
passed through a 100 × 4.1 mm C18 column (Waters
Corporation). A Waters 2487 Absorbance Detector was
set at 260 nm (Waters Corporation). Identification and
quantification of ATP in samples were accomplished
using retention time and area under the curve produced
by injecting an ATP standard (Sigma-Aldrich) into the
HPLC system under identical conditions. ATP standard
calibration concentration ranged from 0 to 500 μM. A
good linear relationship was observed between ATP
concentrations against area under the curve (R2 = 0.999)
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culated based on area under the curve and was normal-
ized against the weight of each extracted tissue.
Cell culture
Cancer cells
The human head and neck cancer cell line, HSC-3
(ATCC) derived from a human tongue SCC, was culti-
vated in Dulbecco’s Modification of Eagle’s Medium
(DMEM) with 4.5 g/L glucose, L-glutamine and sodium
pyruvate, supplemented with 10% fetal bovine serum
(FBS), 25 μg/mL fungizone, 100 μg/mL streptomycin
sulfate, and 100 U/mL penicillin G and cultivated at 37°C
in 5% CO2.
Neurons
Mouse TG neurons were harvested and cultured as pre-
viously described [27]. Briefly, BALB/c mice were eutha-
nized with isoflurane. Trigeminal ganglia were removed,
transferred into HBSS and enzyme-digested by incuba-
tion with papain (Worthington), collagenase type II
(CLS2) (Worthington), and dispase type II (MB). Disso-
ciated neurons were plated on glass coverslips coated
with poly-d-lysine and laminin and maintained for
approximately 2 hr at 37°C at 5% CO2/95% air in F12
media (Gibco BRL) supplemented with 10% FBS.
Co-culture
Coverslips containing TG neurons were transferred into
culture dishes containing HSC-3 cells in fresh F12
medium supplemented with 10% FBS and cultured for
1 day before co-culture experiments. Anti-NGF antibody
(R&D Systems) was used at 50 ng/ml and added directly
into culture medium.
Mouse models
Six to eight week-old female athymic, immunocomprom-
ised (BALB/c nu/nu) mice and BALB/c mice were pur-
chased (Charles River Laboratories). Mice were housed in
a temperature-controlled room on a 12:12 light:dark cycle
(0600–1800 h light), with ad libitum access to food and
water. All experiments were performed according to
the policies and recommendations of the International
Association for the Study of Pain and approved by the
New York University Institution Animal Care and Use
Committee.
SCC supernatant model
HSC-3 cells were grown in 10 cm cell culture dishes to
90% confluency; the medium was changed to serum-free
DMEM (2 mL volume), and incubated for 48 hours.
Culture supernatant was then collected on the day of
injection. 50 μl of SCC supernatant was injected into
the right hind paw of BALB/c mice anesthetized withisoflurane. Control mice received the same volume of
serum-free DMEM in the right hind paw. 3 mg/kg or
10 mg/kg A-317491 was directly dissolved into 50 μl
SCC supernatant. AF-353 was first dissolved in DMSO
(Sigma-Aldrich) and the solution was then added into
50 μl of SCC supernatant. Both A-317491 and AF-353
are strong antagonists to P2X3 and P2X2/3 receptors,
and are weak antagonists to P2X2 receptors. AF-353 is
a more potent antagonist, with high oral bioavailability
and CNS penetration [14,28].
Paw SCC model
A paw cancer pain model was created by inoculating 106
HSC-3 cells, suspended in vehicle consisting of 50 μl
volume DMEM and Matrigel™ (Becton Dickinson & Co),
into the right hind paw of athymic BALB/c nu/nu mice.
Subcutaneous injection of 3 mg/kg A-317491 or 3 mg/kg
AF-353 was performed daily from day 10 through day 28
post-inoculation. Mouse hind paw volume was measured
by using a plethysmometer (IITC Life Science) (Additional
file 1: Figure S1C).
Tongue SCC model
The tongue SCC model was produced in athymic BALB/c
nu/nu mice as previously described [22]. The anatomic
and functional features of this mouse cancer model
parallel those found in HNSCC patients [22]. After
baseline Dolognawmeter gnaw times were established,
BALB/c nude mice were inoculated with 50 μl total
volume (of 106) HSC-3 cells in DMEM and Matrigel™
into the tongue through a transoral approach. Control
mice received 50 μl of vehicle injection. 20 μl of an
ATP-hydrolyzing enzyme apyrase (100 μM, Sigma-
Aldrich), A-317491 (3 mg/kg, Sigma-Aldrich), AF-353
(3 mg/kg, Afferent Pharmaceuticals) or normal saline




Testing was performed by an observer blinded to the
experimental groups. The paw withdrawal threshold
was measured by an electronic von Frey anesthesi-
ometer (IITC Life Sciences). Paw withdrawal threshold
was defined as the force (g) sufficient to elicit a distinct
paw withdrawal flinch upon application of the probe tip.
A mean of eight withdrawal thresholds was calculated.
Orofacial function measurement
Behavioral testing with the Dolognawmeter was per-
formed as previously described [29]. Briefly, each animal
was placed in a tube in which access to escape was
obstructed by a series of two polymer dowels. The ani-
mal voluntarily gnaws through the two dowels to escape
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is connected to a digital timer. When a bar is severed by
the mouse, a timer dedicated to the respective dowel is
stopped. Animals were trained for 10 gnawing trials and
then a baseline gnaw-time was established for each
animal. Gnawing behavior was measured 15 minutes
after drug treatment on post-inoculation 14. Data were
analyzed as percent change of gnaw-time from baseline
for each mouse.
Immunofluorescence
Coverslips with plated neurons were fixed with 4% PFA
and blocked with superblock (Thermo Fisher Scientific)
for 30 min. Human HNSCC tissues were resected and
fixed with 4% PFA, dehydrated, embedded in paraffin,
and cut into 8-μm sections. Sections were then deparaf-
finized and blocked with superblock. H&E staining was
performed to confirm cancer lesions. For immunofluor-
escence labeling, neurons or tissue sections were then
incubated for 24 h at 4°C in rabbit anti-P2X3 (1:500,
Alomone Labs) and goat anti-P2X2 (1:500, Santa Cruz
Biotechnology). The sections were then washed in
phosphate-buffered saline (PBS) with Triton X-100 and
incubated in secondary antibody chicken anti-rabbit
Alexa-594 (1:1000, Invitrogen) and donkey anti-goat
Alexa-488 (1:1000, Invitrogen) in a dark chamber for
2 hours at room temperature. Control experiments were
performed by incubation in secondary antibody alone and
by applying P2X2 blocking peptides (Santa Cruz Biotech-
nology), and P2X3 blocking peptides (Alomone Labs).
The coverslips or sections were washed and visualized
with images acquired using a Nikon Ti Eclipse micro-
scope (Nikon).
Microdialysis
Mice were anesthetized with ketamine/xylazine (9:1, vol/vol).
A microdialysis probe (CMA30, CMA-Microdialysis)
was inserted through a guide cannula into the tongue of
mice with tongue SCC or normal mice. Tongues were
perfused with PBS at a constant flow rate of 1.0 μl/min
using a CMA-402 microsyringe pump. After a 30 minute
equilibration period, samples were collected for 90 minutes
and kept at 4°C. Six mice were used in each group.
ATP Luminescence assay
ATP concentration in the mouse tongue microdialysate
samples and HNSCC supernatant were determined using
ENLITEN ATP assay kit (Promega). Luminescence inten-
sity was determined using a luminometer (GloMax-Multi
Detection System, Promega). Calibration curves were
obtained using standard ATP samples with subtraction of
background luminescence of PBS. For SCC supernatant,
5×104, 105, 2×105 cells were seeded onto separate culture
plates and incubated in 3 ml of serum-free medium.Media was collected after 12 hours of incubation and ATP
quantification was performed immediately.
Calcium imaging
Cultured TG neurons were loaded with 1 μM of the cell
permeable calcium sensitive dye, Fura 2 AM (Molecular
Probes) for 30 min and washed with HBSS before use.
Coverslips containing neurons were placed in a chamber
with constant infusion of phenol-red free DMEM at room
temperature. Fluorescence was detected by a Nikon
Eclipse TI microscope (Nikon) fitted with a 20x fluor/
NA 0.75 objective lens. Fluorescence images of 340 and
380 excitation wavelengths were collected and analyzed
with the TI Element Software (Nikon). For drug treat-
ments, neurons were pre-incubated with either AF-353
(1 μM), or A-317491 (1 μM) for 20 min prior to SCC
supernatant application. Cells were counted as SCC super-
natant responsive if the 340/380 ratio is ≥0.2 from baseline.
Electrophysiology
Coverslips with neurons were transferred to a recording
chamber and perfused continuously with external solu-
tion containing the following (in mM): 140 NaCl, 4 KCl,
2 MgCl2, 2 CaCl2, 10 glucose and 10 HEPES (pH 7.3
adjusted with NaOH, 320 mOsm/kg with sucrose), at
room temperature. Patch pipettes were double-pulled
(P-2000, Sutter, CA) from quartz glass capillaries (Q100-
50-10, Sutter). They were adjusted to 2–8 MΩ when
filled with a pipette solution (in mM): KCl 145, MgCl2 3,
CaCl2 2.25, EGTA 1, HEPES 10 (pH 7.3 adjusted with
KOH, 310 mOsm). After establishing the whole-cell con-
figuration, the voltage was clamped at −60 mV using
Axopatch 200B amplifier (Axon Instrument) and con-
trolled by Clampex software (pClamp 10.2; Axon Instru-
ment). DMEM, SCC supernatant, and drugs were applied
using a fast-step SF-77B perfusion system (Warner Instru-
ment) with three-barreled pipette placed near the cell.
Current amplitudes were measured at the peak of the
inward component.
qRT-PCR
Human oral SCC and anatomically matched, contralat-
eral normal oral epithelium from 10 oral cancer patients
were surgically removed and immediately snap frozen in
liquid nitrogen and stored at −80°C. Fresh TG neurons
from mice with tongue SCC or normal mice were
collected and stored at −80°C (n = 8 in each group).
Tissues were homogenized and total RNA isolation of
each sample was conducted with a Qiagen AllPrep
DNA/RNA Micro Kit (Qiagen Inc.). Reverse transcription
was carried out with a High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems Inc.) according to the
manufacturer’s instructions. Quantitative real-time PCR
was performed with the Taqman Gene Expression Assay
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from Life Technologies (Mouse P2X3: Mn00523699_m1;
Mouse P2X2: Mn00462952_m1). The housekeeping gene
β-actin was used as the internal control gene. Relative
quantification analysis of gene expression data was calcu-
lated using the 2 −ΔΔCt method.
Statistical analysis
SigmaPlot 11.0 for Windows was used to perform the
statistical analysis. Student’s t-test, paired t-test, one-way
Analysis of Variance (ANOVA) with a Tukey multiple
comparisons post-hoc test, two-way ANOVA, and re-
gression analysis were used where appropriate. Signifi-
cance level was set at *P < 0.05, **P < 0.01, ***P < 0.001.
Results were presented as mean ± SEM.Figure 1 ATP, P2X2, and P2X3 in human HNSCC microenvironment an
from tumor and matched normal tissue harvested from the same patient. b
normal sites (Contra) (n = 10, Student’s t-test). c. Pain scores of functional sh
sharpness and intensity, respectively (n = 13, Student’s t-test). d. Mean score
spontaneous pain (Q1, 3, 5) (Student’s t-test). e. ATP concentration in extrac
regression). f. Representative H&E and immunofluorescence staining (P2X2,
adjacent sections of the SCC. Scale bar: 100 μm.Results
The human cancer microenvironment is characterized by
(i) a high ATP concentration, which correlates with pain
intensity, and (ii) innervation by nerves expressing P2X2
and P2X3 subunits
The ATP concentration in extracted HNSCC tissue was
significantly higher than in anatomically matched healthy
tissues from the same patients as measured by HPLC
(Figure 1a and b). HNSCC patients reported both spon-
taneous and functional pain; however, functional pain
was significantly higher than spontaneous pain (Figure 1c
and d). Mean pain scores correlated positively with ATP
concentration from extracted cancer tissue (Figure 1e).
Patient demographic data, tumor location and staging are
presented in Additional file 1: Table S1. We investigatedd pain. a. Representative HPLC chromatograms showing ATP peaks
. Tumor tissues (Ipsi) had higher levels of ATP compared to matched
arpness and intensity were significantly higher than spontaneous
s of functional pain (Q2, 4, 6, 7, 8) were significantly higher than
ted cancer tissue correlated positively with mean pain scores (linear
P2X3, merged) of a human tongue SCC. Sections were taken from
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in the nerves innervating human HNSCC tissue. We
observed intense P2X2 immunoreactivity on nerves
associated with human HNSCC; the majority of these
nerves also displayed immunoreactivity to our P2X3
probe (Figure 1f ). HNSCC cells in patients’ tumor sec-
tions did not exhibit appreciable levels of P2X2 and
P2X3 immunoreactivity (Additional file 2: Figure S1a).Figure 2 ATP in the HNSCC microenvironment activates neurons and
increases with HNSCC cell number (One-way ANOVA). b. ATP concentration
mouse tongues (n = 6 in each group, Student’s t-test). c. Representative tra
supernatant, and 50 mM KCl (positive control). Each line represents one ce
of TG neurons responding to HNSCC supernatant based on calcium imagin
response to HNSCC supernatant in presence and absence of A-317491 and
vehicle controls in ATP-responding TG neurons (One-way ANOVA). g. HNSC
nociception compared to DMEM injection. AF-353 reversed HNSCC superna
injection. After 180–210 minutes, both antagonists reversed HNSCC supern
ANOVA compared to HNSCC supernatant group). h. Oral function was sign
hydrolyzing enzyme apyrase, AF-353 and A-317491 significantly improved o
compared to HNSCC mice with vehicle treatment). i. In mice with paw SCC
reduced mechanical nociception compared to vehicle (n = 8 for each grouHNSCC secretes ATP which activates P2X2 and P2X3
subunits on TG neurons and produces pain
HNSCC cells (HSC-3 cell line) secreted ATP spontan-
eously and the ATP concentration positively correlated
with increasing cell number (Figure 2a). Microdialysate
collected from mouse tongue HNSCCs in situ showed
significantly elevated levels of extracellular ATP com-
pared to microdialysate collected from normal tonguescauses pain through P2X2/3 heterotrimers. a. ATP concentration
in microdialysate of mouse tongue SCC was higher than normal
ces of calcium response (A340/A380) to culture media (DMEM), HNSCC
ll. d. Preincubation with A-317491 or AF-353 reduced the percentage
g (χ2-test). e. Representative whole cell recordings of TG neurons in
AF-353. f. A-317491 and AF-353 reduced current ratio compared to
C supernatant injection into the mouse hind paw caused mechanical
tant-induced mechanical nociception measured at 30–60 minutes post
atant-induced mechanical nociception (n = 7-9 in each group, One-way
ificantly impaired in tongue SCC mice compared to naïve mice. ATP
ral function in HNSCC mice (n = 6-10 in each group; One-way ANOVA
, twice daily (BID) treatment of AF-353 and A-317491 significantly
p; Two-way ANOVA).
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vated by ATP released from HNSCC in mouse models.
We characterized P2X2 and P2X3 on TG neurons
based on their response to HNSCC supernatant using
calcium imaging and electrophysiology. When we ap-
plied HNSCC supernatant to TG neurons, we observed
an increased intracellular Ca2+ concentration in 39%
(72/185) of TG neurons (Figure 2c-d). Application of
two different classes of P2X3 and P2X2/3 receptor
antagonists, a competitive antagonist A-317491 and an
allosteric antagonist AF-353, resulted in a significant
decrease in the percentage of neurons responding to
HNSCC supernatant (Figure 2d): 16% (16/99) follow-
ing A-317491 treatment, and 15% (14/96) following
AF-353 treatment. We next used electrophysiology to
characterize TG neurons following the application of
ATP and HNSCC supernatant (Figure 2e-f ). Whole-
cell patch-clamp recording showed a sustained inward
current in 52% (44/84) of cultured TG neurons (Figure 2e)
and no transient current was recorded following
HNSCC supernatant application. A-317491 dose-de-
pendently inhibited the supernatant-induced current,
while the inhibitory effect of AF-353 plateaued at 1 μM
(Figure 2f ).
To examine the effect of ATP, P2X2 and P2X3
receptors in HNSCC pain in vivo, we used three differ-
ent mouse models of HNSCC. HNSCC supernatant
injected into the mouse hind paw produced mechan-
ical nociception (Figure 2g), which was fully reversed
for 1 hour by intraplantar injection of 3 mg/kg AF-
353, and for the full 3.5 hours with 10 mg/kg AF-353.
Reversal of supernatant-induced pain with 3 mg/kg
A-317491 was achieved for 3–3.5 hours after injection
(Figure 2g). These results possibly reflected the dif-
ferential rates of disposition following local injection
of the polar A-317491 and lipophilic AF-353, respect-
ively [14,28,30]. To examine the effect of ATP from can-
cer on orofacial sensory function, we inoculated HNSCC
cells into the mouse tongue. Mice with tongue cancer
exhibited significant orofacial nociception (i.e., increased
gnaw time) compared to control mice in a quantita-
tive orofacial pain assay (Figure 2h) [29]. The ATP-
hydrolyzing enzyme apyrase, AF-353 or A-317491
significantly reduced oral nociception in mice with
HNSCC with a single intratumor injection (Figure 2h).
To test the long-lasting effect of AF-353 and A-317491
on cancer growth and mechanical nociception, we
inoculated HNSCC cells into the mouse hind paw
and paw volume was quantified as an index for can-
cer growth. Systemically (subcutaneously) adminis-
tered A-317491 and AF-353 over several weeks reduced
HNSCC-induced mechanical nociception (Figure 2i),
without affecting tumor growth (Additional file 2:
Figure S1b).Co-culture in HNSCC induces P2X2/3 plasticity in TG
neurons in a NGF-dependent manner
To investigate the role of NGF on P2X receptors, we
co-cultured HNSCC cells and mouse TG neurons. TG
neurons exhibited both transient (P2X3 homotrimers) and
sustained current (P2X2 homotrimers and/or P2X2/3
heterotrimers) in response to 30 μM ATP (Figure 3a).
Following co-culture with HNSCC cells, sustained ATP
current in some TG neurons was enhanced and pro-
longed, while properties of other TG neurons showing
transient currents were unchanged (Figure 3a and 3b).
Adding anti-NGF into the co-culture media signifi-
cantly reduced amplitude and density of the sustained
ATP current in TG neurons, without affecting the tran-
sient ATP current (Figure 3a and 3b). Measurement of
the sustained current in TG neurons and reversal by
anti-NGF as a function of cell diameter revealed that
the responsive neurons were medium-sized (Figure 3c),
i.e., those expressing both P2X2 and P2X3 subunits [7].
Other electrophysiological parameters of recorded neu-
rons were not affected by co-culture or the addition of
anti-NGF (Additional file 1: Table S2).
To further characterize specific P2X receptor subtypes
in cancer pain, we stained cultured TG neurons using
immunofluorescence (Figure 3d) and compared these re-
sults with patch-clamp recordings. In normal TG neuron
culture, 14% of neurons exclusively expressed the P2X3
subunit, 17% of neurons exclusively expressed P2X2, and
19% neurons expressed both subunits (Figure 3e, Table 1).
These observations corroborated the patch-clamp record-
ings, in which ATP application activated transient
current in 17% neurons and sustained current in 34%
neurons (Table 1). Co-culture significantly increased
the percentage of neurons expressing both P2X sub-
units, from 19% at baseline to 33% after co-culture
(Figure 3e, Table 1). Anti-NGF significantly reduced
the percentage of co-cultured neurons expressing both
P2X subunits (Figure 3e). Patch-clamp experiments
showed that the number of cells exhibiting sustained
ATP-induced current increased from 34% in normal
neurons to 44% following co-culture (Table 1). Per-
centage of neurons exhibiting a transient ATP-induced
current was similar between normal (17%) and co-cultured
neurons (14%). Our electrophysiology results demonstrated
that co-culture or anti-NGF only affected medium-
sized neurons which contain both P2X2 and P2X3
subunits. Similarly, immunofluorescence revealed that
co-culture increased, while anti-NGF reduced, the
percentage of cells expressing P2X2 and P2X3 subunits
on TG neurons (Figure 3e). Co-culture or anti-NGF
treatment significantly affected P2X3 but not P2X2
immunofluorescence intensity (Figure 3f). P2X2 mRNA
was significantly increased in TG neurons harvested
from mice with tongue cancer compared to normal
Figure 3 HNSCC induces neuronal P2X2/3 plasticity that is reversed by anti-NGF. a. Sustained ATP current (top panel) is enhanced and
prolonged following SCC co-culture; anti-NGF added into the co-culture reduced the sustained ATP current. Transient ATP current (lower panel) is
not affected by either co-culture or anti-NGF. b. Sustained ATP current density is increased by co-culture (One-way ANOVA), and is reversed
by anti-NGF. c. Dot plot of sustained ATP current in different diameter neurons. Co-culture increased current in medium-sized TG neurons;
this increased current was reversed by anti-NGF. d. Representative immunofluorescence images of P2X2 and P2X3 expression in TG neurons.
e. HNSCC co-culture increased the percentage of neurons expressing P2X2 and P2X3 subunits. Anti-NGF treatment significantly reduced
percentage of neurons expressing P2X3 but not P2X2 subunits. The significant increase in the percentage of neurons that express both
subunits following co-culture was reversed by anti-NGF application (One-way ANOVA). f. P2X2 immunofluorescence intensity was not changed after
co-culture or anti-NGF treatment. P2X3 immunofluorescence intensity was significantly increased following co-culture, and was reduced by anti-NGF
(one-way ANOVA). g. In mice with tongue HNSCC, mRNA expression for P2X2 was increased, while P2X3 expression was unchanged in TG neurons
(Student’s t-test).
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on P2X2 mRNA expression. No significant difference was
observed for P2X3 mRNA expression between cancer and
normal mice.
Discussion
In the present report we elucidated a mechanism within





P2X3 only P2X2 + P2X
P2X2 only P2X2 +
Normal 14% 17% 19%
Co-culture 11% 17% 33%
Co-culture + Anti-NGF 11% 21% 20%We identified ATP as a potent algogenic mediator in
both HNSCC patients and animal models. We evaluated
differential roles of P2X2 and P2X3 subunits in HNSCC
pain using calcium imaging, patch clamping, and mo-
lecular approaches. Using three different animal models
of HNSCC pain with application of an ATP degrading
enzyme, and two antagonists specific to P2X3 and P2X2/3
receptors, we confirmed the role of these receptors inconditions revealed by immunofluorescent labeling and
Patch clamp recording
2/3 Transient current Sustained current
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genic mediators like NGF, can modulate the plasticity of
P2X2 and P2X3 subunits to amplify painful signals.
Evidence suggesting the involvement of ATP, P2X2
and P2X3 in pain signaling has been obtained mostly
from rodent sensory systems at the level of the spinal
cord and DRGs. Few studies have been conducted in
trigeminal system. Furthermore, there has always been a
question whether these findings in rodents can be trans-
lated into human physiology. A recent study by Serrano
et al. reported that monkey and human DRG neurons
do not express appreciable levels of P2X2 subunit,
contrary to rodent sensory neurons [16]. The authors also
demonstrated that monkey DRG neurons have functional
P2X3 activity but lack functional P2X2/3 receptors. In
transfected HEK293 cells, the authors found that the
pharmacology of P2X3 receptors was different between
rodents and primates. In our study, we report for the first
time that the human HNSCC microenvironment contains
high levels of ATP which correlates with patients’ pain
intensity. We showed that in the human trigeminal
system, both P2X3 and P2X2 subunits are expressed in
the peripheral terminals of primary afferent neurons.
Future studies need to confirm whether P2X2 and P2X3
subunits are expressed in normal tongue tissues, and
whether pathological conditions like cancer lead to
upregulation of P2X receptors in humans [15,25]. Func-
tional studies are also needed to compare trigeminal
P2X2, P2X3, and P2X2/3 receptors between human and
rodents.
Importantly, we identified P2X2/3 expressing neurons
as a player in cancer pain, while neurons exclusively
expressing P2X2 and P2X3 have minimal contributions.
We showed that the human HNSCC microenvironment
is innervated by nerve fibers exhibiting immunoreactiv-
ity to both of our P2X2 and P2X3 probes. Colocalization
of P2X2 and P2X3 subunits in nerve fibers innervating
the tongue strongly implicate the presence of P2X2/3
heterotrimeric receptors. We found that the ATP con-
taining HNSCC supernatant induced a sustained current
in mice trigeminal neurons, suggesting the involvement
of P2X2 homotrimers and/or P2X2/3 heterotrimers.
Co-culture of cancer cells with trigeminal neurons en-
hanced sustained ATP current in medium sized neurons,
with no effect on transient ATP current (i.e. P2X3 recep-
tors). Co-culture significantly increased the percentage
of neurons expressing both P2X subunits. Consistent
with previous studies [5], we found that these neurons
co-expressing P2X2 and P2X3 subunits are medium
sized. The effect of anti-NGF was also only observed in
medium sized neurons exhibiting sustained current to
ATP application, and co-expressing both P2X subunits.
These collective results point out the importance of
P2X2/3 heterotrimers in HNSCC pain and resonatewith previous proposals that P2X2/3 receptors are
major players in inflammatory and neuropathic models
of chronic pain [10,11,31].
HNSCC pain is unique in its localization at the primary
site; most other cancers hurt once they metastasize,
usually to bone [2,4]. Our data supports the peripheral
mechanism of ATP and its receptors in HNSCC-induced
mechanical nociception. First, high ATP concentrations
in the peripheral human cancer tissues correlates with
patients’ reported pain levels. Second, reducing ATP
levels in HNSCC supernatant by the ATP degrading
enzyme apyrase decreases HNSCC-induced mechanical
nociception. Third, peripherally injected P2X2/3 antago-
nists also reduce HNSCC-induced mechanical nocicep-
tion. Since A-317491 does not penetrate the blood–brain
barrier [14], its anti-nociceptive effect is restricted to the
periphery. It should be noted that although both AF-353
and A-317491 completely blocked HNSCC supernatant
induced pain in the paw withdrawal assays, our calcium
imaging, patch clamping, and two other orthotropic
HNSCC models only demonstrated a partial role for
P2X2/3 receptors. As both AF-353 and A-317491 pre-
dominantly antagonize P2X3 subunits [14,28,30], the
observed remaining response could be gated through
P2X2 subunits. Regardless of the receptors, our data
strongly suggest that ATP serves as an important medi-
ator in HNSCC-induced pain.
Our study demonstrated that cancer cells induce P2X2/
3 plasticity with enhanced ATP sensitivity in trigeminal
ganglia. Such plasticity is modulated by NGF, another
major cancer-released mediator [22]. Two known mod-
ulators of P2X receptor sensitivity and expression are
glial-derived nerve growth factor (GDNF) and NGF
[18,23,24]. The proalgesic action of NGF is believed to
be predominantly mediated by TrkA receptors with
subsequent PKC activation and calcium release [32]. In
trigeminal ganglia, TrkA colocalizes with P2X3 [5,24].
We have previously shown that HNSCC produces NGF
[22] but not GDNF [33], and further that NGF plays an
important role in HNSCC proliferation and pain [22].
Using a pharmacologic approach (i.e., anti-NGF treat-
ment), we showed that NGF alters the expression levels of
P2X2 and P2X3 subunits as demonstrated by whole-cell
recordings and immunofluorescent staining. Increased
receptor activity could also be explained by changes in
membrane subunit composition or phosphorylation of
the subunits, as proposed in other studies [24].
Conclusions
We identified HNSCC as a major source of ATP in the
HNSCC microenvironment and established the import-
ance of heterotrimeric P2X2/3 receptors on trigeminal
sensory fibers in HNSCC cancer pain. Our data also
highlighted the importance of cancer cells in driving
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http://www.actaneurocomms.org/content/2/1/62function-evoked pain and neuronal plasticity (i.e., receptor
upregulation and functional modulation) by tumorigenic
mediators including NGF. We validated the ATP-P2X2/3
mechanism using preclinical animal models and human
patients. Novel therapeutics that can potently antagonize
P2X2/3 might have strong analgesic efficacy for human
cancer pain.
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